AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
AbbVie (ABBV) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
February 4, 2026 7:51 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.71, $0.06 better than the analyst estimate of $2.65. Revenue for the quarter came in at $16.62 billion versus the consensus estimate of $16.39 billion.
GUIDANCE:
AbbVie sees FY2026 EPS of $14.37-$14.57, versus the consensus of $14.22.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More